Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

9P - small-scale ROS1 Aberrations: functional impact and therapeutic potential

Date

15 Oct 2022

Session

Poster display session

Presenters

Moritz Glaser

Citation

Annals of Oncology (2022) 33 (suppl_8): S1383-S1430. 10.1016/annonc/annonc1095

Authors

M. Glaser1, C. von Levetzow2, S. Michels2, L. Nogova2, M. Katzenmeier2, C. Wömpner2, J. Schmitz2, E. Bitter2, I. Terjung2, E. Passmann2, D. Schaufler2, A. Eisert2, R.N. Fischer2, R. Riedel2, S. Hahne2, S. Merkelbach-Bruse2, R. Büttner2, J. Wolf2, M. Scheffler2

Author affiliations

  • 1 University Hospital Cologne, Köln/DE
  • 2 University Hospital of Cologne, Köln/DE
More

Abstract 9P

Background

ROS1-directed Tyrosine-Kinase-Inhibitors (TKIs) target activating fusions in the ROS1 proto-oncogene efficiently in non-small cell lung cancer (NSCLC) patients. Besides solvent-front mutations (SFMs) in resistance to targeted therapy, ROS1 aberrations other than fusions remain biologically unexplored. Driving on our thus far clinical investigations, we aimed at determining the functional impact and the potential to act as a drug target.

Methods

Tumor samples from NSCLC patients were screened with two next-generation sequencing (NGS) panels. Patients with activating ROS1 fusions, SFMs and benign Single-Nucleotide Polymorphisms (SNPs) were excluded using the gnomAD database. The Provean and PolyPhen-2 tools predicted the functional impact of the detected aberrations. ChimeraX was used for drug binding analysis.

Results

Of 8072 patients analyzed by NGS between 2018 and 2022, 110 (1.4%) patients harbored small-scale ROS1 aberrations. Our cohort consists of 113 aberrations leading to 95 (84.1%) missense, 12 (10.6%) truncating and 1 (0.1%) in-frame aberrations. In 10% of patients ROS1 aberration was mutually exclusive and most ROS1 aberrations were transitions (55%). Polyphen predicts 75.5% of aberrations to be ‘possibly’ (6.4%), respectively ‘probably damaging’ (68.1%, mean score 0.75, median score 0.999). Provean predicts 50% of aberrations to be ‘deleterious’. Polyphen-2 and Provean coherently predict 46.8% of aberrations to be ‘deleterious’ respectively ‘possibly/probably damaging’. Amid the tyrosine kinase domain almost all aberrations are predicted to be ‘probably damaging’ respectively ‘deleterious’ by both tools coherently and feature a higher-than-average score. Besides, no distinct molecular pattern occurs. The M2029T and R2083T missense mutations interfere with single hydrogen-bonds and Van-Der-Waals forces in the ROS1 drug-binding pocket between the respective residues and the TKIs crizotinib and lorlatinib. However, drug binding analysis revealed that the overall binding of the TKIs is not affected.

Conclusions

This evidence proves a functional and deleterious impact of specific aberrations and indicates a high potential to be targetable. We warrant further studies to elaborate these findings in vitro and in vivo.

Legal entity responsible for the study

M. Scheffler.

Funding

Has not received any funding.

Disclosure

L. Nogova: Financial Interests, Personal, Other, honoraria: Pfizer, Celgene, Novartis, Roche, Boehringer Ingelheim, Janssen Pharmaceuticals, Bristol Myers Squibb. D. Schaufler: Financial Interests, Personal, Other, honoraria: BMS, Boehringer Ingelheim, MSD, Novartis, Roche, Healthcare Consulting Cologne, AbbVie. R.N. Fischer: Financial Interests, Personal, Other, honoraria: BMS, MSD, Roche, Boehringer Ingelheim, AstraZeneca. R. Riedel: Financial Interests, Personal, Other, honoraria: Boehringer Ingelheim, Novartis. R. Büttner: Financial Interests, Personal, Other, consultant: Pfizer, Novartis. J. Wolf: Financial Interests, Personal, Other, honoraria: AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Chugai, Ignyta, Lilly, MSD, Novartis, Pfizer, Roche; Financial Interests, Personal, Other, consultant: AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Chugai, Ignyta, Lilly, MSD, Novartis, Pfizer, Roche. M. Scheffler: Financial Interests, Personal, Other, consultant: BMS, Boehringer Ingelheim, Takeda, Roche; Financial Interests, Personal, Other, travel funding: Boehringer Ingelheim, Mediolanum. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.